Siemens Healthcare subsidiary PETNet Solutions is expanding its imaging biomarker production capabilities in Nottingham, England, to enhance its ability to produce new biomarkers as investigational medicine products (IMPs) in the U.K.
The IMPs include a proprietary hypoxic agent developed by Siemens of Malvern, PA, to identify tumor tissues with low oxygen supply, and a leading investigational amyloid agent for PET imaging of beta-amyloid deposits in the brain.
Related Reading
PETNet builds network, July 7, 2010
Siemens' PETNet offers free F-18 NaF, March 19, 2000
Siemens to supply F-18 NaF via PETNet, March 8, 2010
PETNet to supply ACRIN trial, November 2, 2009
PETNet signs supply deal with Lantheus, June 11, 2009
Copyright © 2010 AuntMinnie.com
